Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)

Axel F Grothey, Mary M. Sugrue, David M. Purdie, Wei Dong, Daniel Sargent, Eric Hedrick, Mark Kozloff

Research output: Contribution to journalArticle

568 Citations (Scopus)

Abstract

Purpose: Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients who had mCRC, a longer-than-expected overall survival (OS) of 25.1 months was reported. The association between various pre-and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined. Patients and Methods: The 1,445 of 1,953 previously untreated patients with mCRC who were enrolled in BRiTE and who experienced disease progression (PD) were classified into three groups: no post-PD treatment (n = 253), post-PD treatment without bevacizumab (no BBP; n = 531), and BBP (n = 642). Relevant baseline and on-study variables, including BBP, were analyzed with a Cox model with respect to their independent effect on survival beyond first PD. Results: Median OS was 25.1 months (95% CI, 23.4 to 27.5 months), and median progression-free survival was 10.0 months in the overall BRiTE population. Baseline and postbaseline factors were well balanced between the BBP and no-BBP groups. Median OS rates were 12.6, 19.9, and 31.8 months in the no post-PD treatment, no-BBP, and BBP groups, respectively. In multivariate analyses, compared with no BBP, BBP was strongly and independently associated with improved survival (HR, 0.48; P < .001). Hypertension that required medication was the only bevacizumab-related safety event that occurred more frequently in the BBP group (24.6% v 19.2%). Conclusion: These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have mCRC.

Original languageEnglish (US)
Pages (from-to)5326-5334
Number of pages9
JournalJournal of Clinical Oncology
Volume26
Issue number33
DOIs
StatePublished - Nov 20 2008

Fingerprint

Observational Studies
Colorectal Neoplasms
Cohort Studies
Safety
Survival
Therapeutics
Bevacizumab
Patient Safety
Proportional Hazards Models
Vascular Endothelial Growth Factor A
Disease-Free Survival
Disease Progression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : Results from a large observational cohort study (BRiTE). / Grothey, Axel F; Sugrue, Mary M.; Purdie, David M.; Dong, Wei; Sargent, Daniel; Hedrick, Eric; Kozloff, Mark.

In: Journal of Clinical Oncology, Vol. 26, No. 33, 20.11.2008, p. 5326-5334.

Research output: Contribution to journalArticle

Grothey, Axel F ; Sugrue, Mary M. ; Purdie, David M. ; Dong, Wei ; Sargent, Daniel ; Hedrick, Eric ; Kozloff, Mark. / Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : Results from a large observational cohort study (BRiTE). In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 33. pp. 5326-5334.
@article{d57bea69328f4a548c8d614f3e772d30,
title = "Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)",
abstract = "Purpose: Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients who had mCRC, a longer-than-expected overall survival (OS) of 25.1 months was reported. The association between various pre-and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined. Patients and Methods: The 1,445 of 1,953 previously untreated patients with mCRC who were enrolled in BRiTE and who experienced disease progression (PD) were classified into three groups: no post-PD treatment (n = 253), post-PD treatment without bevacizumab (no BBP; n = 531), and BBP (n = 642). Relevant baseline and on-study variables, including BBP, were analyzed with a Cox model with respect to their independent effect on survival beyond first PD. Results: Median OS was 25.1 months (95{\%} CI, 23.4 to 27.5 months), and median progression-free survival was 10.0 months in the overall BRiTE population. Baseline and postbaseline factors were well balanced between the BBP and no-BBP groups. Median OS rates were 12.6, 19.9, and 31.8 months in the no post-PD treatment, no-BBP, and BBP groups, respectively. In multivariate analyses, compared with no BBP, BBP was strongly and independently associated with improved survival (HR, 0.48; P < .001). Hypertension that required medication was the only bevacizumab-related safety event that occurred more frequently in the BBP group (24.6{\%} v 19.2{\%}). Conclusion: These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have mCRC.",
author = "Grothey, {Axel F} and Sugrue, {Mary M.} and Purdie, {David M.} and Wei Dong and Daniel Sargent and Eric Hedrick and Mark Kozloff",
year = "2008",
month = "11",
day = "20",
doi = "10.1200/JCO.2008.16.3212",
language = "English (US)",
volume = "26",
pages = "5326--5334",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer

T2 - Results from a large observational cohort study (BRiTE)

AU - Grothey, Axel F

AU - Sugrue, Mary M.

AU - Purdie, David M.

AU - Dong, Wei

AU - Sargent, Daniel

AU - Hedrick, Eric

AU - Kozloff, Mark

PY - 2008/11/20

Y1 - 2008/11/20

N2 - Purpose: Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients who had mCRC, a longer-than-expected overall survival (OS) of 25.1 months was reported. The association between various pre-and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined. Patients and Methods: The 1,445 of 1,953 previously untreated patients with mCRC who were enrolled in BRiTE and who experienced disease progression (PD) were classified into three groups: no post-PD treatment (n = 253), post-PD treatment without bevacizumab (no BBP; n = 531), and BBP (n = 642). Relevant baseline and on-study variables, including BBP, were analyzed with a Cox model with respect to their independent effect on survival beyond first PD. Results: Median OS was 25.1 months (95% CI, 23.4 to 27.5 months), and median progression-free survival was 10.0 months in the overall BRiTE population. Baseline and postbaseline factors were well balanced between the BBP and no-BBP groups. Median OS rates were 12.6, 19.9, and 31.8 months in the no post-PD treatment, no-BBP, and BBP groups, respectively. In multivariate analyses, compared with no BBP, BBP was strongly and independently associated with improved survival (HR, 0.48; P < .001). Hypertension that required medication was the only bevacizumab-related safety event that occurred more frequently in the BBP group (24.6% v 19.2%). Conclusion: These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have mCRC.

AB - Purpose: Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients who had mCRC, a longer-than-expected overall survival (OS) of 25.1 months was reported. The association between various pre-and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined. Patients and Methods: The 1,445 of 1,953 previously untreated patients with mCRC who were enrolled in BRiTE and who experienced disease progression (PD) were classified into three groups: no post-PD treatment (n = 253), post-PD treatment without bevacizumab (no BBP; n = 531), and BBP (n = 642). Relevant baseline and on-study variables, including BBP, were analyzed with a Cox model with respect to their independent effect on survival beyond first PD. Results: Median OS was 25.1 months (95% CI, 23.4 to 27.5 months), and median progression-free survival was 10.0 months in the overall BRiTE population. Baseline and postbaseline factors were well balanced between the BBP and no-BBP groups. Median OS rates were 12.6, 19.9, and 31.8 months in the no post-PD treatment, no-BBP, and BBP groups, respectively. In multivariate analyses, compared with no BBP, BBP was strongly and independently associated with improved survival (HR, 0.48; P < .001). Hypertension that required medication was the only bevacizumab-related safety event that occurred more frequently in the BBP group (24.6% v 19.2%). Conclusion: These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have mCRC.

UR - http://www.scopus.com/inward/record.url?scp=56749169353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749169353&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.16.3212

DO - 10.1200/JCO.2008.16.3212

M3 - Article

C2 - 18854571

AN - SCOPUS:56749169353

VL - 26

SP - 5326

EP - 5334

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -